A. Sandler

761 total citations
35 papers, 604 citations indexed

About

A. Sandler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, A. Sandler has authored 35 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in A. Sandler's work include Cancer Immunotherapy and Biomarkers (20 papers), Lung Cancer Treatments and Mutations (13 papers) and Lung Cancer Research Studies (11 papers). A. Sandler is often cited by papers focused on Cancer Immunotherapy and Biomarkers (20 papers), Lung Cancer Treatments and Mutations (13 papers) and Lung Cancer Research Studies (11 papers). A. Sandler collaborates with scholars based in United States, Italy and Germany. A. Sandler's co-authors include Marcin Kowanetz, Achim Rittmeyer, M. Ballinger, David R. Gandara, Joan H. Schiller, Solange Peters, Rafat Ansari, Marina Chiara Garassino, Everett E. Vokes and Daniel Waterkamp and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

A. Sandler

35 papers receiving 594 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Sandler United States	16	524	390	120	98	80	35	604
Giannicola DʼAddario Switzerland	6	411 0.8×	318 0.8×	124 1.0×	84 0.9×	38 0.5×	8	540
Maria Bassanelli Italy	10	419 0.8×	326 0.8×	99 0.8×	33 0.3×	68 0.8×	23	547
Christopher Sumey United States	7	387 0.7×	292 0.7×	91 0.8×	100 1.0×	50 0.6×	17	482
Beung‐Chul Ahn South Korea	12	497 0.9×	366 0.9×	106 0.9×	42 0.4×	81 1.0×	38	621
Cláudia Casanova Italy	9	273 0.5×	267 0.7×	100 0.8×	50 0.5×	128 1.6×	24	421
Yun Fan China	13	479 0.9×	337 0.9×	86 0.7×	73 0.7×	83 1.0×	52	580
Francesca Sperandi Italy	12	346 0.7×	239 0.6×	137 1.1×	73 0.7×	60 0.8×	50	511
Laure Hirsch France	9	297 0.6×	246 0.6×	183 1.5×	24 0.2×	116 1.4×	16	517
Emily Roarty United States	10	348 0.7×	330 0.8×	79 0.7×	16 0.2×	138 1.7×	24	480
Linpeng Zheng China	10	207 0.4×	150 0.4×	77 0.6×	32 0.3×	71 0.9×	17	304

Countries citing papers authored by A. Sandler

Since Specialization

Citations

This map shows the geographic impact of A. Sandler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Sandler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Sandler more than expected).

Fields of papers citing papers by A. Sandler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Sandler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Sandler. The network helps show where A. Sandler may publish in the future.

Co-authorship network of co-authors of A. Sandler

This figure shows the co-authorship network connecting the top 25 collaborators of A. Sandler. A scholar is included among the top collaborators of A. Sandler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Sandler. A. Sandler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jotte, Robert M., Federico Cappuzzo, Ihor Vynnychenko, et al.. (2019). OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC. Journal of Thoracic Oncology. 14(10). S243–S244. 15 indexed citations

Mok, Tony, Martin Reck, Leora Horn, et al.. (2018). IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). Annals of Oncology. 29. ix173–ix173. 8 indexed citations

Rizvi, Naiyer A., David R. Gandara, Benjamin Solomon, et al.. (2018). P2.17-27 IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy. Journal of Thoracic Oncology. 13(10). S863–S863. 7 indexed citations

Liu, Stephen V., Aaron S. Mansfield, Aleksandra Szczęsna, et al.. (2018). PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. Journal of Thoracic Oncology. 13(10). S185–S186. 5 indexed citations

Haddad, Robert I., Deborah J. Wong, Ye Guo, et al.. (2018). IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology. 29. viii397–viii397. 17 indexed citations

Pietras, Richard J., Haipeng Xu, Xiao Hu, et al.. (2018). P1.04-33 Retrospective Descriptive Analysis of Metformin with Atezolizumab in Advanced Non-Small Cell Lung Cancer in The OAK Trial. Journal of Thoracic Oncology. 13(10). S538–S539. 8 indexed citations

Lin, Steven H., Lin Xiao, Daniel L. Clay, et al.. (2018). OA01.06 DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S320–S321. 20 indexed citations

Gadgeel, S., Marcin Kowanetz, Wenbo Zou, et al.. (2017). Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study. Annals of Oncology. 28. v460–v461. 13 indexed citations

Jassem, Jacek, Filippo de Marinis, David R. Spigel, et al.. (2017). IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC. Annals of Oncology. 28. ii50–ii50. 3 indexed citations

10.

Rittmeyer, Achim, David C. Smith, Johan Vansteenkiste, et al.. (2017). Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR). Pneumologie. 71(S 01). S1–S125. 4 indexed citations

11.

Barlési, Fabrice, K. Park, Fortunato Ciardiello, et al.. (2016). Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Annals of Oncology. 27. vi581–vi581. 56 indexed citations

12.

Kowanetz, Marcin, Wei Zou, David S. Shames, et al.. (2016). Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC. Annals of Oncology. 27. vi23–vi23. 34 indexed citations

13.

Reck, Martin, Vassiliki A. Papadimitrakopoulou, Federico Cappuzzo, et al.. (2016). Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy. Annals of Oncology. 27. vi451–vi451. 4 indexed citations

14.

Horn, Leora, Martin Reck, Tony Mok, et al.. (2016). A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133). Annals of Oncology. 27. vi496–vi496. 3 indexed citations

15.

Marinis, Filippo de, Jacek Jassem, David R. Spigel, et al.. (2016). 480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts). Annals of Oncology. 27. ix154–ix154. 4 indexed citations

16.

Herbst, Roy S., Filippo de Marinis, Jacek Jassem, et al.. (2015). 355TiP Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC. Annals of Oncology. 26. ix103–ix103. 3 indexed citations

17.

Mok, Tony, Federico Cappuzzo, Robert M. Jotte, et al.. (2015). 356TiP Phase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC. Annals of Oncology. 26. ix103–ix103. 3 indexed citations

18.

Gerber, David E., Suzanne E. Dahlberg, A. Sandler, et al.. (2013). Baseline tumour measurements predict survival in advanced non-small cell lung cancer. British Journal of Cancer. 109(6). 1476–1481. 30 indexed citations

19.

Hanna, Nasser H., A. Sandler, Corey J. Langer, et al.. (2005). Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). Journal of Clinical Oncology. 23(16_suppl). LBA7004–LBA7004. 27 indexed citations

20.

Loehrer, Patrick J., et al.. (1995). Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.. Journal of Clinical Oncology. 13(5). 1209–1214. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact